Reportlinker Adds Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists' Survey
NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0487242/Triple-Negative-Metastatic-Breast-Cancer-Clinical-Insights-from-a-US-Oncologists-Survey.html
Triple Negative
A patient specific case scenario progressing throughout the report, presented to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on clinical decisions. Patient progression reveals:
• Decisions in treatment throughout patient stages
• Factors influencing their decisions
• Barriers to optimal care
• Confidence in treatment.
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Negative Metastatic Breast Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
• Design messages to advance brand performance
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Triple Negative Metastatic Breast Cancer
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer
Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.1
Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.2
Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3
Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.4
Confidence managing patient with triple negative metastatic breast cancer
Figure 3.5
Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.1
Treatment of progressive triple negative metastatic breast cancer
Figure 3.2
Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.3
Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3. 4
Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.5
Changing therapy to manage neuropathy
Figure 3.6
Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.7
Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.8
Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.9
Chapter 4. Summary
Appendix A: Survey Instrument
Companies mentioned
Celgene, Pfizer, Astra Zeneca, Genentech/Roche, Novartis, Eisai, Eli Lilly, Abbott Labs, Sanofi-aventis, GlaxoSmithKline
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article